Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and Nivolumab in Advanced Solid Tumors
NCT02476123Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2015
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mogamulizumab in solid tumor, sponsored by Kyowa Kirin. Primary endpoints: Number of subjects reporting adverse events, Number of subjects reporting serious adverse events and 3 more. Started Jun 2015; status: completed.
02
Drugs
mogamulizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02476123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476123.